Diagnostic Name (Manufacturer),Indication - Sample Type,Drug Trade Name (Generic) NDA / BLA,Biomarker(s),Biomarker(s) (Details),PMA / 510(k) /513(f)(2) / HDE (Approval / Clearance / Grant Date)
therascreenPDGFRA RGQ PCR Kit (QIAGEN GmbH),Gastrointestinal Stromal Tumors (GIST) - Tissue,AYVAKIT (Avapritinib)NDA 212608 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212608),PDGFRA,D842V mutation,P210002(06/29/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210002)
"Abbott RealTime IDH1 (Abbott Molecular, Inc.)",Acute Myeloid Leukemia - Peripheral Blood or Bone Marrow,Tibsovo (ivosidenib)NDA 211192 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211192),IDH1,"R132 mutations (R132C, R132H, R132G, R132S, and R132L)",P170041(07/20/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170041)
"Abbott RealTime IDH1 (Abbott Molecular, Inc.)",Myelodysplastic Syndromes (MDS) - Peripheral Blood or Bone Marrow,Tibsovo (ivosidenib)NDA 211192 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211192),IDH1,"R132 mutations (R132C, R132H, R132G, R132S, and R132L)",P170041/S007(10/24/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170041S007)
"Abbott RealTime IDH2 (Abbott Molecular, Inc.)",Acute Myeloid Leukemia - Peripheral Blood or Bone Marrow,Idhifa (enasidenib)NDA 209606 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209606),IDH2,"R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W",P170005(08/01/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170005)
Bond Oracle HER2 IHC System (Leica Biosystems),Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2 (HER2),HER-2 protein overexpression,P090015(04/18/2012) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090015)
"BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)",Ovarian Cancer - Whole Blood,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,Mutations,P140020(12/19/2014) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?start_search=1&PMANumber=P140020&SupplementType=NONE)
"BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)",Breast Cancer - Whole Blood,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,Mutations,P140020/S012(01/12/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020S012)
"BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)",Breast Cancer - Whole Blood,Talzenna (talazoparib)NDA 211651 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process),BRCA1andBRCA2,Mutations,P140020/S015(10/16/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020S015)
"BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)",Ovarian Cancer - Whole Blood,Rubraca (rucaparib)NDA 209115 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115),BRCA1andBRCA2,Mutations,P140020/S016(10/16/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020S016)
"BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)",Pancreatic Cancer - Whole Blood,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,Mutations,P140020/S019(12/27/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020S019)
"BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Whole Blood,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,Mutations,P140020/S020(05/19/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020S020)
"cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)",Melanoma - Tissue,Zelboraf (vemurafenib)NDA 202429 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202429),BRAF,V600E,P110020(08/17/2011) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110020)
"cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)",Melanoma - Tissue,Cotellic (cobimetinib)NDA 206192in combination with Zelboraf (vemurafenib)NDA 202429 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192),BRAF,V600E or V600K,P110020/S016(11/07/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110020S016)
"cobas EGFR Mutation Test v1 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tarceva (erlotinib)NDA 021743 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021743),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120019(07/15/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019)
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tagrisso (osimertinib)NDA 208065 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),T790M,P120019/S007(11/13/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S007)
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tagrisso (osimertinib)NDA 208065 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120019/S016(04/18/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S016)
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tagrisso (osimertinib)NDA 208065 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120019/S018(04/18/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S018)
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue or Plasma,Iressa (gefitinib)NDA 206995 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120019/S019(08/22/0218) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S019)
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue or Plasma,Iressa (gefitinib)NDA 206995 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P120019/S031(10/27/2020)Group Labeling, see table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S031)"
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue or Plasma,Tarceva (erlotinib)NDA 021743 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021743),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P120019/S031(10/27/2020)Group Labeling, see table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S031)"
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue or Plasma,Gilotrif (afatinib)NDA 201292 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201292),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P120019/S031(10/27/2020)Group Labeling, see table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S031)"
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue or Plasma,Tagrisso (osimertinib)NDA 208065 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P120019/S031(10/27/2020)Group Labeling, see table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S031)"
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tagrisso (osimertinib)NDA 208065 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),T790M,P150044(09/28/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150044)
"cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tarceva (erlotinib)NDA 021743 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021743),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P150047(06/01/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150047)
"cobas EZH2 Mutation Test (Roche Molecular Systems, Inc.)",Follicular Lymphoma Tumor - Tissue,Tazverik (tazemetostat)NDA 213400 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213400),EZH2,"Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of theEZH2gene",P200014(06/18/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p200014)
"cobas KRAS Mutation Test (Roche Molecular Systems, Inc.)",Colorectal Cancer - Tissue,Erbitux (cetuximab)BLA 125084 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),KRAS,Mutations in codons 12 and 13 ofKRASgene,P140023(05/07/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140023)
"cobas KRAS Mutation Test (Roche Molecular Systems, Inc.)",Colorectal Cancer - Tissue,Vectibix (panitumumab)BLA 125147 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),KRAS,Mutations in codons 12 and 13 ofKRASgene,P140023(05/07/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140023)
"Dako EGFR pharmDx Kit (Dako North America, Inc.)",Colorectal Cancer - Tissue,Erbitux (cetuximab)BLA 125084 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),EGFR (HER1),EGFR (HER1) protein expression,P030044(02/12/2004) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030044)
"Dako EGFR pharmDx Kit (Dako North America, Inc.)",Colorectal Cancer - Tissue,Vectibix (panitumumab)BLA 125147 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),EGFR (HER1),EGFR (HER1) protein expression,P030044/S002(09/27/2006) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030044s002)
FerriScan (Resonance Health Analysis Services Pty Ltd),Non-Transfusion-Dependent Thalassemia - Tissue,Exjade (deferasirox)NDA 021882 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021882),Liver iron concentration imaging,Liver iron concentration based on the proton transverse relaxation rate of MRI images,DEN130012 / K124065(01/23/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN130012)
"FoundationFocus CDxBRCA Assay (Foundation Medicine, Inc.)",Ovarian Cancer - Tissue,Rubraca (rucaparib)NDA 209115 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115),BRCA1andBRCA2,BRCA1andBRCA2alterations,P160018(12/19/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160018)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Gilotrif (afatinib)NDA 201292 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201292),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Iressa (gefitinib)NDA 206995 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tarceva (erlotinib)NDA 021743 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021743),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tagrisso (osimertinib)NDA 208065 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),T790M,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Alecensa (alectinib)NDA 208434 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208434),ALK,ALKrearrangements,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Xalkori (crizotinib)NDA 202570 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202570),ALK,ALKrearrangements,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Zykadia (ceritinib)NDA 211225 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211225),ALK,ALKrearrangements,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tafinlar (dabrafenib)NDA 202806in combination with Mekinist (trametinib)NDA 204114 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806),BRAF,V600E,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),ERBB2(HER2) amplification,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Breast Cancer - Tissue,Perjeta (pertuzumab)BLA 125409 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125409),ERBB2(HER2),ERBB2(HER2) amplification,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Breast Cancer - Tissue,Kadcyla (ado-trastuzumab emtansine)BLA 125427 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125427),ERBB2(HER2),ERBB2(HER2) amplification,P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Colorectal Cancer - Tissue,Erbitux (cetuximab)BLA 125084 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),KRAS,KRASwild-type (absence of mutations in codons 12 and 13),P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Colorectal Cancer - Tissue,Vectibix (panitumumab)BLA 125147 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),KRASandNRAS,"KRASwild-type (absence of mutations in exons 2, 3, and 4) andNRASwild type (absence of mutations in exons 2, 3, and 4)",P170019(11/30/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)
"FoundationOne CDx (Foundation Medicine, Inc.)",Melanoma - Tissue,Mekinist (trametinib)NDA 204114 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114),BRAF,V600E and V600K,"P170019(11/30/2017)Group Labeling, See table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019)"
"FoundationOne CDx (Foundation Medicine, Inc.)",Ovarian Cancer - Tissue,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,BRCA1andBRCA2alterations,P170019/S004(07/01/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S004)
"FoundationOne CDx (Foundation Medicine, Inc.)",Breast Cancer - Tissue,Piqray (alpelisib)NDA 212526 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212526),PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",P170019/S006(12/03/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S006)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tagrisso (osimertinib)NDA 208065 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P170019/S008(07/01/2019)Group Labeling, See table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S008)"
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tabrecta (capmatinib)NDA 213591 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213591),MET,METsingle nucleotide variants and indels that lead toMETexon 14 skipping,P170019/S011(05/06/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S011)
"FoundationOne CDx (Foundation Medicine, Inc.)",Cholangiocarcinoma - Tissue,Pemazyre (pemigatinib)NDA 213736 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213736),FGFR2,FGFR2fusions and select rearrangements,P170019/S013(04/17/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S013)
"FoundationOne CDx (Foundation Medicine, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Tissue,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),Homologous recombination repair (HRR) genes,"BRCA1,BRCA2,ATM,BARD1,BRIP1,CDK12,CHEK1,CHEK2,FANCL,PALB2,RAD51B,RAD51C,RAD51DandRAD54Lalterations",P170019/S015(05/19/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S015)
"FoundationOne CDx (Foundation Medicine, Inc.)",Solid Tumors - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),TMB,TMB ≥ 10 mutations per megabase,P170019/S016(06/16/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S016)
"FoundationOne CDx (Foundation Medicine, Inc.)",Solid Tumors - Tissue,Vitrakvi (larotrectinib)NDA 210861 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210861),"NTRK1,NTRK2andNTRK3","NTRK1,NTRK2andNTRK3fusions",P170019/S017(10/23/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S017)
"FoundationOne CDx (Foundation Medicine, Inc.)",Solid Tumors - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),MSI-High,Microsatellite instability-High (MSI-H),P170019/S029(02/18/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S029)
"FoundationOne CDx (Foundation Medicine, Inc.)",Solid Tumors - Tissue,Rozlytrek (entrectinib)NDA 212725 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725),"NTRK1, NTRK2 and NTRK3","NTRK1, NTRK2 and NTRK3 fusions",P170019/S014(06/07/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S014)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Rozlytrek (entrectinib)NDA 212725 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725),ROS1,ROS1 fusions,P170019/S014(06/07/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S014)
"FoundationOne CDx (Foundation Medicine, Inc.)",Melanoma - Tissue,Tecentriq (atezolizumab)BLA 761034in combination with Cotellic (cobimetinib)NDA 206192and Zelboraf (vemurafenib)NDA 202429 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034),BRAF,BRAFV600 mutations,P170019/S030(01/19/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S030)
"FoundationOne CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,BRAFTOVI (encorafenib)NDA210496in combination with MEKTOVI (binimetinib)NDA210498 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496),BRAF,V600E,P170019/S039(10/11/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S039)
"FoundationOne CDx (Foundation Medicine, Inc.)",Solid Tumors - Tissue,RETEVMO (selpercatinib)NDA214246 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246),RET,RET fusions,P170019/S043(10/06/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S043)
"FoundationOne CDx (Foundation Medicine, Inc.)",Breast Cancer - Tissue,TRUQAP (capivasertib)NDA218197in combination with FASLODEX (fulvestrant)NDA021344 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=218197),PIK3CA,AKT1/PTENalterations,P170019/S048(11/16/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S048)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Iressa (gefitinib)NDA 206995 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P190032(08/26/2020)P190032/S008(12/19/2022)Group Labeling, See table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p190032)"
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tagrisso (osimertinib)NDA 208065 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P190032(08/26/2020)P190032/S008(12/19/2022)Group Labeling, See table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p190032)"
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tarceva (erlotinib)NDA 021743 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021743),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P190032(08/26/2020)P190032/S008(12/19/2022)Group Labeling, See table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p190032)"
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,BRAFTOVI (encorafenib)NDA210496in combination with MEKTOVI (binimetinib)NDA210498 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496),BRAF,V600E,P190032/S011(10/11/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S011)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Plasma,Rubraca (rucaparib)NDA 209115 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115),BRCA1andBRCA2,BRCA1andBRCA2alterations,P190032(08/26/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p190032)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tabrecta (capmatinib)NDA 213591 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213591),MET,METsingle nucleotide variants and indels that lead toMETexon 14 skipping,P190032/S001(07/15/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S001)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Rozlytrek (entrectinib)NDA 212725 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725),ROS1,ROS1 fusions,P190032/S004(12/22/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S004)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Solid Tumors - Plasma,Rozlytrek (entrectinib)NDA 212725 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725),"NTRK1, NTRK2,andNTRK3fusions",NTRK1/2/3fusions,P190032/S004(12/22/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S004)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Alecensa (alectinib)NDA 208434 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208434),ALK,ALKrearrangements,P200006(10/26/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p200006)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Breast Cancer - Plasma,Piqray (alpelisib)NDA 212526 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212526),PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",P200006(10/26/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p200006)
"Guardant360 CDx (Guardant Health, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tagrisso (osimertinib)NDA 208065 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065),EGFR(HER1),"EGFRexon 19 deletions,EGFRexon 21 L858R, and T790M",P200010(08/07/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p200010)
"Guardant360 CDx (Guardant Health, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Rybrevant (amivantamb)BLA 761210 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761210),EGFR(HER1),EGFRexon 20 insertions,P200010/S001(05/21/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010S001)
"Guardant360 CDx (Guardant Health, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Lumakras (sotorasib)NDA 214665 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214665),KRAS,G12C,P200010/S002(05/28/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010S002)
"Guardant360 CDx (Guardant Health, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,ENHERTU (fam-trastuzumab deruxtecan-nxki)BLA 761139 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761139),ERBB2,ERBB2 Activating Mutations (SNVs And Exon 20 Insertions),P200010/S008(08/11/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010S008)
"Guardant360 CDx (Guardant Health, Inc.)",Breast Cancer - Plasma,Orserdu (elacestrant)NDA 217639 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217639),ESR1,ESR1missense mutations between codons 310 and 547,P200010/S010(01/27/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010S010)
HER2 CISH pharmDx Kit (Dako Denmark A/S),Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu (ERBB2) gene amplification,P100024(11/30/2011) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p100024)
HER2 FISH pharmDx Kit (Dako Denmark A/S),Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P040005(05/03/2005) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p040005)
HER2 FISH pharmDx Kit (Dako Denmark A/S),Gastric and Gastroesophageal Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P040005/S005(10/20/2010) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040005S005)
HER2 FISH pharmDx Kit (Dako Denmark A/S),Breast Cancer - Tissue,Perjeta (pertuzumab)BLA 125409 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125409),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P040005/S006(06/08/2012) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040005S006)
HER2 FISH pharmDx Kit (Dako Denmark A/S),Breast Cancer - Tissue,Kadcyla (ado-trastuzumab emtansine)BLA 125427 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125427),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P040005/S009(02/22/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040005S009)
HercepTest (Dako Denmark A/S),Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2 (HER2),HER-2 protein overexpression,P980018(09/25/1998) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018)
HercepTest (Dako Denmark A/S),Gastric and Gastroesophageal Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2 (HER2),HER-2 protein overexpression,P980018/S010(10/20/2010) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018S010)
HercepTest (Dako Denmark A/S),Breast Cancer - Tissue,Perjeta (pertuzumab)BLA 125409 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125409),ERBB2 (HER2),HER-2 protein overexpression,P980018/S015(06/08/2012) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018S015)
HercepTest (Dako Denmark A/S),Breast Cancer - Tissue,Kadcyla (ado-trastuzumab emtansine)BLA 125427 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125427),ERBB2 (HER2),HER-2 protein overexpression,P980018/S016(02/22/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018S016)
"INFORM HER-2/neu (Ventana Medical Systems, Inc.)",Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P940004(12/30/1997) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p940004)
"InSite Her-2/neu (CB11) Monoclonal Antibody (Biogenex Laboratories, Inc.)",Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2 (HER2),HER2protein overexpression,P040030(12/22/2004) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p040030)
"KIT D816V Assay (ARUP Laboratories, Inc.)",Aggressive Systemic Mastocytosis - Bone Marrow,Gleevec (imatinib mesylate)NDA 021588 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588),KIT,D816V,H140006(12/18/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375586)
"LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)",Acute Myelogenous Leukemia - Peripheral Blood or Bone Marrow,Rydapt (midostaurin)NDA 207997 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207997),FLT3(ITD/TDK),ITD mutations and TKD mutations D835 and I836,P160040(04/28/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160040)
"LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)",Acute Myelogenous Leukemia - Peripheral Blood or Bone Marrow,Xospata (gilterinib)NDA 211349 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211349),FLT3(ITD/TDK),ITD mutations and TKD mutations D835 and I836,P160040/S002(11/28/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160040S002)
MRDx BCR-ABL Test (MolecularMD Corporation),Chronic Myeloid Leukemia - Peripheral Blood,Tasigna (nilotinib)NDA 022068 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022068),t(9;21) Philadelphia chromosome,BCR-ABLfusion,K173492(12/22/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173492)
"Myriad myChoice CDx (Myriad Genetic Laboratories, Inc.)",Ovarian Cancer - Tissue,Lynparza (olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),Myriad HRD,Deleterious or suspected deleterious mutations inBRCA1andBRCA2genes and/or positive Genomic Instability Score),P190014/S003(05/08/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190014S003)
nAbCyte Anti-AAVRh74var HB-FE Assay (Labcorp Drug Development),Moderate to severe Hemophilia B patients - Serum,BEQVEZ (fidanacogene elaparvovec)BLA 125786 (/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez),AAVRh74var capsid neutralizing antibodies,Neutralizing antibodies to the adeno-associated virus serotype Rh74var (AAVRh74var) capsid,H230005(04/25/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=533832)
"ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)",Colorectal Cancer - Tissue,Erbitux (cetuximab)BLA 125084 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),KRAS,KRASwild-type (absence of mutations in codons 12 and 13),P200011(07/30/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200011)
"ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)",Colorectal Cancer - Tissue,Vectibix (panitumumab)BLA 125147 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),KRAS,KRASwild-type (absence of mutations in codons 12 and 13),P200011(07/30/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200011)
"ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,A tyrosine kinase inhibitor approved by FDA for that indication,EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,"P200011(07/30/2021)Group Labeling, See table below (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200011)"
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tafinlar (dabrafenib)NDA 202806in combination with Mekinist (trametinib)NDA 204114 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806),BRAF,V600E,P160045(06/22/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045)
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Xalkori (crizotinib)NDA 202570 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202570),ROS1,ROS1fusions,P160045(06/22/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045)
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Iressa (gefitinib)NDA 206995 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P160045(06/22/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045)
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Gavreto (pralsetinib)NDA 213721 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213721),RET,RETfusions,P160045/S019(09/04/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045s019)
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Rybrevant (amivantamb)BLA 761210 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761210),EGFR(HER1),Exon 20 insertion mutations,P160045/S027(12/01/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045s027)
Oncomine Dx Target Test (Life Technologies Corporation),Cholangiocarcinoma - Tissue,Tibsovo (ivosidenib)NDA 211192 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211192),IDH1,Single nucleotide variants,P160045/S028(08/25/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045s028)
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,ENHERTU (fam-trastuzumab deruxtecan-nxki)BLA 761139 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761139),ERBB2,ERBB2 Activating Mutations (SNVs And Exon 20 Insertions),P160045/S035(08/11/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045S035)
Oncomine Dx Target Test (Life Technologies Corporation),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Retevmo (selpercatinib)NDA 213246 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246),RET,RETfusions,P160045/S031(09/21/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045s031)
Oncomine Dx Target Test (Life Technologies Corporation),Medullary Thyroid Cancer (MTC) - Tissue,Retevmo (selpercatinib)NDA 213246 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246),RET,"RET mutations (SNVs, MNVs, and deletions)",P160045/S031(09/21/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045s031)
Oncomine Dx Target Test (Life Technologies Corporation),Thyroid Cancer (TC) - Tissue,Retevmo (selpercatinib)NDA 213246 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246),RET,RETfusions,P160045/S031(09/21/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p160045s031)
PathVysion HER-2 DNA Probe Kit (Abbott Molecular Inc.),Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P980024(12/11/1998) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p980024)
"PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)",Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2 (HER2),HER-2 protein overexpression,P990081(11/28/2000) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p990081)
"PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)",Breast Cancer - Tissue,Kadcyla (ado-trastuzumab emtansine)BLA 125427 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125427),ERBB2 (HER2),HER-2 protein overexpression,P990081/S039(05/03/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990081S039)
"PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)",Breast Cancer - Tissue,Enhertu (fam-trastuzumab deruxtecan-nxki)BLA 761139 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761139),ERBB2 (HER2),HER-2 protein overexpression,P990081/S047(09/30/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p990081s047)
"PDGFRB FISH Assay (ARUP Laboratories, Inc.)",Myelodysplastic Syndrome/Myeloproliferative Disease - Bone Marrow,Gleevec (imatinib mesylate)NDA 021588 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588),PDGFRB,PDGFRBgene rearrangement at 5q31~33,H140005(12/18/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375585)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),PD-L1,PD-L1 protein expression,P150013(10/02/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Cervical Cancer - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),PD-L1,PD-L1 protein expression,P150013/S009(06/12/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S009)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Head and Neck Squamous Cell Carcinoma (HNSCC) - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),PD-L1,PD-L1 protein expression,P150013/S014(06/10/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S014)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Esophageal Squamous Cell Carcinoma (ESCC) - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),PD-L1,PD-L1 protein expression,P150013/S016(07/30/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S016)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Triple-Negative Breast Cancer (TNBC) - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),PD-L1,PD-L1 protein expression,P150013/S020(11/13/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S020)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Libtayo (cemiplimab-rwlc)BLA 761097 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761097),PD-L1,PD-L1 protein expression [Tumor Proportion Score (TPS) ≥ 50%],P150013/S021(02/22/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S021)
"PD-L1 IHC 28-8 pharmDx (Dako North America, Inc.)",Non-small cell lung cancer (NSCLC) - Tissue,Opdivo (nivolumab)BLA 125554in combination with Yervoy (ipilimumab)BLA 125377 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125554),PD-L1,PD-L1 protein expression (tumor cell staining ≥1%),P150025/S013(05/15/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150025S013)
"PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)",Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Tissue,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),PD-L1,PD-L1 protein expression,P150013/S027(11/07/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013S027)
"POMC/PCSK1/LEPR CDx Panel (PreventionGenetics, LLC)",Obesity - Blood or Saliva,Imcivree (setmelanotide acetate)NDA 213793 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213793),"POMC,PCSK1andLEPR",Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance,DEN200059(01/21/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN200059)
SeCore CDx HLA Sequencing System (One Lambda Inc.),Uveal Melanoma – Whole Blood,Kimmtrak (tebentafusp-tebn)BLA 761228 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761228),HLA,HLA-A*02:01,BR220737(11/28/2022) (/vaccines-blood-biologics/substantially-equivalent-510k-device-information/br220737-secore-cdx-hla-sequencing-system)
SPOT-LIGHT HER2 CISH Kit (Life Technologies Corporation),Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P050040(07/01/2008) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p050040)
"therascreenEGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Gilotrif (afatinib)NDA 201292 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201292),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120022(07/12/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120022)
"therascreenEGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Iressa (gefitinib)NDA 206995 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120022/S001(07/10/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120022S001)
"therascreenEGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Gilotrif (afatinib)NDA 201292 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201292),EGFR(HER1),"L861Q, G719X and S7681",P120022/S016(01/12/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120022S016)
"therascreenEGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Vizimpro (dacomitinib)NDA 211288 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211288),EGFR(HER1),Exon 19 deletion or exon 21 L858R substitution mutation,P120022/S018(09/27/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120022S018)
"therascreenKRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)",Colorectal Cancer - Tissue,Vectibix (panitumumab)BLA 125147 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),KRAS,"G12A, G12D, G12R, G12C, G12S, G12V, G13D",P110027(05/23/2014) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p110027)
"therascreenKRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Lumakras (sotorasib)NDA 214665 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214665),KRAS,G12C,P110027/S012(05/28/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110027S012)
"therascreenKRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)",Colorectal Cancer - Tissue,Erbitux (cetuximab)BLA 125084 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),KRAS,"G12A, G12D, G12R, G12C, G12S, G12V, G13D",P110030(07/06/2012) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p110030)
therascreenBRAF V600E RGQ PCR Kit (QIAGEN GmbH),Colorectal Cancer - Tissue,Braftovi (encorafenib)NDA 210496in combination with Erbitux (cetuximab)BLA 125084 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496),BRAF,V600E,P190026(04/15/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190026)
therascreenFGFR RGQ RT-PCR Kit (QIAGEN Manchester Ltd.),Urothelial Cancer - Tissue,Balversa (erdafitinib)NDA 212018 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212018),FGFR3,"Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1andFGFR3-TACC3v3)",P180043(04/12/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P180043)
therascreenPIK3CA RGQ PCR Kit (QIAGEN GmbH),Breast Cancer - Tissue or Plasma,Piqray (alpelisib)NDA 212526 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212526),PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",P190001(05/24/2019)P190004(05/24/2019) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190001)
THXID BRAF Kit (bioMérieux Inc.),Melanoma - Tissue,Mekinist (trametinib)NDA 204114 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114),BRAF,V600E or V600K,P120014(05/29/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p120014)
THXID BRAF Kit (bioMérieux Inc.),Melanoma - Tissue,Tafinlar (dabrafenib)NDA 202806 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806),BRAF,V600E,P120014(05/29/2013) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p120014)
THXID BRAF Kit (bioMérieux Inc.),Melanoma - Tissue,Braftovi (encorafenib)NDA 210496in combination with Mektovi (binimetinib)NDA 210498 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496),BRAF,V600E or V600K,P120014/S008(06/27/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120014S008)
"Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Xalkori (crizotinib)NDA 202570 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202570),ALK,ALK protein expression,P140025(06/12/2015) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140025)
"Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Zykadia (ceritinib)NDA 211225 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211225),ALK,ALK protein expression,P140025/S005(05/26/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140025S005)
"Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Alecensa (alectinib)NDA 208434 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208434),ALK,ALK protein expression,P140025/S006(11/06/2017) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140025S006)
"Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Lorbrena (lorlatinib)NDA 210868 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210868),ALK,ALK protein expression,P140025/S014(03/03/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140025S014)
"Ventana FOLR1 (FOLR-2.1) RxDx Assay(Ventana Medical Systems, Inc.)","Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - Tissue",Elahere (mirvetuximab soravtansine-gynx)BLA 761310 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761310),FOLR1,FOLR1 protein expression,P220006(11/14/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220006)
"Ventana HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems, Inc.)",Breast Cancer - Tissue,Herceptin (trastuzumab)BLA 103792 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792),ERBB2(HER2),HER-2/neu(ERBB2) gene amplification,P190031(07/28/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p190031)
"Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)",Endometrial Carcinoma (EC) - Tissue,Jemperli (dostarlimag-gxly)BLA 761174 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761174),Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",P200019(04/22/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200019)
"Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)",Solid Tumors,Keytruda (pembrolizumab)BLA 125514 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",P210001/S001(03/21/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210001S001)
"Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)",Endometrial Carcinoma (EC) - Tissue,Keytruda (pembrolizumab)BLA 125514in combination with Lenvima (lenvatinib)NDA 206947 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),proficient mismatch repair (pMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",P210001/S002(06/16/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210001S002)
"Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc.)",Urothelial Carcinoma - Tissue,Tecentriq (atezolizumab)BLA 761034 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034),PD-L1,PD-L1 protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area),P160002(05/18/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160002)
"Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tecentriq (atezolizumab)BLA 761034 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034),PD-L1,PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]),P160002/S006(07/02/2018) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160002S006)
"Ventana PD-LI (SP263) Assay (Ventana Medical Systems, Inc)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Tecentriq (atezolizumab)BLA 761034 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034),PD-L1,PD-L1 protein expression,P160046/S010(10/15/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160046S010)
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Xalkori (crizotinib)NDA 202570 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202570),ALK,ALKgene rearrangements,P110012(08/26/2011) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p110012)
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.),Non-Small Cell Lung Cancer (NSCLC) - Tissue,Alunbrig (brigatinib)NDA 208772 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208772),ALK,ALKgene rearrangements,P110012/S020(05/22/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110012S020)
"Vysis CLL FISH Probe Kit (Abbott Molecular, Inc.)",B-cell Chronic Lymphocytic Leukemia - Peripheral Blood,Venclexta (venetoclax)NDA 208573 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208573),TP53,Deletion chromosome 17p (17p-),P150041(04/11/2016) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p150041)
"Abbott RealTime IDH1 (Abbott Molecular, Inc.)",Acute Myeloid Leukemia - Peripheral Blood or Bone Marrow,Rezlidhia (olutasidenib)NDA 215814 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215814),IDH1,"R132 mutations (R132C, R132H, R132G, R132S, and R132L)",P170041/S006(12/01/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170041S006)
"Agilent Resolution ctDx FIRST assay (Resolution Bioscience, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Krazati (adagrasib)NDA 216340 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340),KRAS,KRAS G12C,P210040(12/12/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210040)
"therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)",Colorectal Cancer - Tissue,Erbitux (cetuximab)BLA 125084 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),KRAS,KRAS wild-type (absence of mutations in codons 12 and 13),P110027/S013(12/02/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110027S013)
"therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)",Non-Small Cell Lung Cancer (NSCLC) - Tissue,Krazati (adagrasib)NDA 216340 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340),KRAS,KRAS G12C,P110027/S013(12/02/2022) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110027S013)
"xT CDx (Tempus Labs, Inc.)",Colorectal Cancer (CRC) - Tissue (Matching Blood/Saliva),Erbitux (cetuximab)BLA 125084 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125084),KRAS,KRAS wild-type (absence of mutations in codons 12 or 13),P210011(04/28/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210011)
"xT CDx (Tempus Labs, Inc.)",Colorectal Cancer (CRC) - Tissue (Matching Blood/Saliva),Vectibix (panitumumab)BLA 125147 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),KRASandNRAS,"KRAS wild-type (absence of mutations in exons 2, 3, or 4) and NRAS wild-type (absence of mutations in exons 2, 3, or 4)",P210011(04/28/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210011)
AAV5 DetectCDx (ARUP Laboratories),Hemophilia A Patients - Plasma,ROCTAVIAN (valoctocogene roxaparvovec-rvox)BLA 125720 (https://purplebooksearch.fda.gov/productdetails?query=125720),Anti-AAV5 Antibodies,Antibodies to the adeno-associated virus serotype 5 (AAV5) viral vector,P190033(06/29/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190033)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Metastatic Colorectal Cancer (mCRC) - Plasma,BRAFTOVI (encorafenib)NDA 210496in combination with cetuximabBLA 125084 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496),BRAF,BRAF V600Ealteration,P190032/S010(06/08/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S010)
"LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)",Acute Myelogenous Leukemia (AML) - Peripheral Blood or Bone Marrow,VANFLYTA (quizartinib)NDA 216993 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216993),FLT3 (ITD/TDK),IDT mutations and TKD mutations D835 and I836,P160040/S011(07/20/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160040S011)
"FoundationOne CDx(Foundation Medicine, Inc.)",Prostate Cancer - Tissue,AKEEGA (niraparib + abiraterone acetate) NDA216793 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216793),BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,P170019/S042(08/11/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S042)
"CRCDx RAS Mutation Detection Assay Kit (EntroGen, Inc.)",Colorectal Cancer (CRC) - Tissue,Vectibix (panitumumab)BLA 125147 (http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147),KRASandNRAS,"KRASwild-type biomarkers (the absence of mutations in exons 2, 3, or 4) andNRASwild-type biomarkers (the absence of mutations in exons 2, 3, or 4)",P220005(09/29/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220005)
Oncomine Dx Target Test (Life Technologies Corporation),Anaplastic Thyroid Cancer (ATC) - Tissue,Tafinlar (dabrafenib)NDA 202806in combination with Mekinist (trametinib)NDA 204114 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806),BRAF,BRAFV600E mutations,P160045/S025(09/29/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045S025)
"SeCore CDx HLA Sequencing System (One Lambda, Inc.)",Synovial sarcoma – Whole blood,Tecelra (afamitresgene autoleucel) -BLA 125789 (https://purplebooksearch.fda.gov/results?query=afamitresgene%20autoleucel&title=tecelra),HLA,"Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles.Exclusion alleles: HLA-A*02:05 and its P-group alleles.",BK241074(08/01/2024) (/vaccines-blood-biologics/substantially-equivalent-510k-device-information/bk241074-secore-cdx-hla-sequencing-system)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - plasma,AKEEGA (niraparib +abiraterone acetate)NDA 216793 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216793),BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,P190032/S014(06/28/ 2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S014)
"TruSight Oncology Comprehensive (Illumina, Inc.)",Solid Tumors - Tissue,Vitrakvi (larotrectinib)NDA 210861 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861),"NTRK1, NTRK2, and NTRK3 fusions",NTRK1/2/3 fusions,P230011(08/21/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230011)
"TruSight Oncology Comprehensive (Illumina, Inc.)",Non-Small Cell Lung Cancer (NSCLC) – Tissue,Retevmo (selpercatinib)NDA 213246 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246),RET,RET fusions,P230011(08/21/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230011)
"MAGE-A4 IHC 1F9 pharmDx (Agilent Technologies, Inc.)",Synovial sarcoma - Tissue,Tecelra (afamitresgene autoleucel) –BLA 125789 (https://purplebooksearch.fda.gov/results?query=afamitresgene%20autoleucel&title=tecelra),Melanoma-associated antigen 4 (MAGE-A4),MAGE-A4 protein overexpression,P230016(08/01/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230016)
Oncomine Dx Target Test (Life Technologies Corporation),Astrocytoma and Oligodendroglioma - Tissue,VORANIGO (vorasidenib) –NDA 218784 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784),"IDH1, IDH2","IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S,andIDH2 R172Gmutations",P160045/S046(09/18/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045S046)
"Ventana PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.)",Non-Small Cell Lung Cancer (NSCLC) – Tissue,Libtayo (cemiplimab-rwlc) –BLA 761097 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761097),PD-L1,PD-L1 protein expression (PD-L1 stained≥50% of tumor cells [TC≥50%]),P160046/S013(03/01/2023) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160046S013)
"FoundationOne CDx (Foundation Medicine, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Tissue,Lynparza (olaparib)NDA 208558in combination with abiraterone (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,BRCA1 and BRCA2 alterations,P170019/S052(08/30/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170019S052)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Plasma,Lynparza (olaparib)NDA 208558in combination with abiraterone (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),BRCA1andBRCA2,BRCA1 and BRCA2 alterations,P190032/S016(08/30/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S016)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Breast Cancer - Plasma,ITOVEBI (inavolisib)NDA 219249in combination with palbociclib and fulvestrant (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249),PIK3CA,Mutations,P190032/S023(10/10/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S023)
"VENTANA CLDN18 (43-14A) RxDx Assay (Ventana Medical Systems, Inc.)",Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Tissue,VYLOY (zolbetuximab) –BLA 761365 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365),Claudin 18 (CLDN18),Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining),P230018(10/18/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230018)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Non-Small Cell Lung Cancer (NSCLC) - Plasma,Tepmetko (tepotinib) –NDA 214096 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214096),MET,MET single nucleotide variants and indels that lead to MET exon 14 skipping,P190032/S015(11/14/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190032S015)
"therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)",Colorectal Cancer - Tissue,Krazati (adagrasib) in combination with Erbitux (cetuximab) –NDA 216340 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216340),KRAS,KRAS G12C,P110027/S017(06/21/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110027S017)
MI Cancer Seek (MCS) (Caris Life Sciences),Breast Cancer - Tissue,Piqray (alpelisib) –NDA 212526 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526),PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
MI Cancer Seek (MCS) (Caris Life Sciences),Colorectal Cancer - Tissue,Vectibix (panitumumab) –BLA 125147 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147),KRAS and NRAS,"KRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4) and NRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4)",P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
MI Cancer Seek (MCS) (Caris Life Sciences),Colorectal Cancer - Tissue,BRAFTOVI (encorafenib)NDA 210496in combination with ERBITUX (cetuximab)BLA 125084 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496),BRAF,V600E,P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
MI Cancer Seek (MCS) (Caris Life Sciences),Melanoma - Tissue,Mekinist (trametinib)NDA 204114 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114),BRAF,V600E or V600K,P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
MI Cancer Seek (MCS) (Caris Life Sciences),Solid Tumors - Tissue,Keytruda (pembrolizumab)BLA 125514 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),MSI-High,Microsatellite instability – High (MSI-H),P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
MI Cancer Seek (MCS) (Caris Life Sciences),Solid Tumors - Tissue,Jemperli (dostarlimab-gxly) –BLA 761223 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761223),MSI-High,Microsatellite instability – High (MSI-H),P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
MI Cancer Seek (MCS) (Caris Life Sciences),Endometrial Carcinoma (EC) - Tissue,Keytruda (pembrolizumab)BLA 125514in combination with Lenvima (lenvatinib)NDA 206947 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514),Not MSI-High,Not Microsatellite instability-high (Not MSI-H),P240010(11/05/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240010)
"PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)","Biliary Tract Cancer (gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) - Tissue",Ziihera (zanidatamab-hrii) –BLA 761416 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416),ERBB2(HER2),HER-2 protein overexpression,P990081/S054(11/20/2024) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990081S054)
"Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)",Solid Tumors,Jemperli (dostarlimag-gxly)BLA 761174 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761174),Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2, and MSH6",P210001(08/17/2021) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P210001)
"FoundationOne Liquid CDx (Foundation Medicine, Inc.)",Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Plasma,Lynparza (Olaparib)NDA 208558 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558),"BRCA1, BRCA2 and ATM","BRCA1, BRCA2, and ATM alterations",P200016(11/06/2020) (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200016)
